Prexige lumiracoxib/COX189 regulatory update

NVS submitted applications for U.S. and European approval of its Prexige lumiracoxib selective COX-2 inhibitor to treat osteoarthritis, rheumatoid arthritis, acute pain and primary dysmenorrhea. ...